Immunotherapy appears better than chemotherapy for aggressive type of skin cancer
(Johns Hopkins Medicine) The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with a rare but aggressive form of skin cancer known as Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Immunotherapy | Merkel Cell Carcinoma | Skin | Skin Cancer | Study